|View printer-friendly version|
|June 12, 2007 1:49 p.m.|
|Teva Receives Favorable Court Decision Regarding Generic Lotrel®; Novartis' Motion For Preliminary Injunction Denied|
Jerusalem, Israel, June 12, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. District Court for the District of New Jersey has vacated a temporary restraining order in effect since May 23, 2007 and denied a motion filed by Novartis for a preliminary injunction related to Teva's amlodipine besylate/ benazepril products, AB rated to Novartis' Lotrel®. In reaching its opinion, the court found that Novartis was not likely to succeed on its allegations of infringement. Teva intends to resume commercial shipments of its amlodipine besylate/ benazepril products immediately. Teva's amlodipine besylate/ benazepril products were approved by the U.S. Food and Drug Administration on May 18, 2007 and Teva immediately commenced commercial shipment. Annual sales of the brand product were approximately $1.4 billion in the U.S. based on IMS sales data.As the first company to file an Abbreviated New Drug Application (ANDA) with a Paragraph IV patent certification, Teva was awarded 180 days marketing exclusivity from the date of initial shipment.